{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:46:16Z","timestamp":1782794776047,"version":"3.54.5"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We report a rare case of clear cell renal cell carcinoma (ccRCC) initially presenting as an isolated symptomatic lumbar vertebral metastasis. A 62-year-old man presented with progressive low back pain radiating to the right lower extremity. Elevated prostate-specific antigen (PSA) levels initially raised strong suspicion for prostate cancer with bone metastasis. However, comprehensive multimodal imaging combined with histopathological evaluation ultimately established the diagnosis of right-sided ccRCC with metastasis to the fourth lumbar vertebra (L4). This case highlights the critical importance of a systematic and multimodal diagnostic approach for bone lesions of unknown primary origin, even in the presence of misleading tumor-specific indicators. We further discuss the diagnostic challenges associated with occult RCC, key differential diagnoses, the role of multidisciplinary team (MDT) management, and current combined therapeutic strategies for metastatic RCC. Clear cell renal cell carcinoma, Bone metastasis, Lumbar vertebra, Unknown primary tumor, Multimodal diagnosis, Multidisciplinary team<\/jats:p>","DOI":"10.3389\/fonc.2026.1853122","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:13Z","timestamp":1782793513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clear cell renal cell carcinoma presenting as isolated symptomatic lumbar vertebral metastasis: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinyan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Practice, Ningbo No.2 Hospital, Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of General Practice, Ningbo No.2 Hospital, Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong\u2019en","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Practice, Ningbo No.2 Hospital, Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200305000-00006","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0034-9","article-title":"An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma","volume":"15","author":"Gr\u00fcnwald","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00345-025-05894-w","article-title":"Symptomatic presentation of renal cell carcinoma","volume":"43","author":"L\u00f3pez-Chaim","year":"2025","journal-title":"World J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: A review","volume":"332","author":"Rose","year":"2024","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.33699\/PIS.2022.101.10.469-477","article-title":"Prognostic factors of renal cell carcinoma","volume":"101","author":"\u010cechov\u00e1","year":"2022","journal-title":"Rozhl Chir"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/10668969241256111","article-title":"Clear cell renal cell carcinoma: A comprehensive review of its histopathology, genetics, and differential diagnosis","volume":"33","author":"Nezami","year":"2025","journal-title":"Int J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20240322-00117","article-title":"Chinese expert consensus on the systemic treatment of advanced clear cell renal cell carcinoma (2024 edition)","volume":"46","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000546879","article-title":"Management of advanced renal cell carcinoma","volume":"49","author":"Zhang","year":"2026","journal-title":"Oncol Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.04.001","article-title":"Management of metastatic renal cell carcinoma: Guideline updates","volume":"11","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae276","article-title":"Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma","volume":"30","author":"Choi","year":"2025","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN guidelines\u00ae Insights: kidney cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:14Z","timestamp":1782793514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1853122"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1853122","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1853122"}}